Catheter Ablation Versus Medication in Atrial Fibrillation and Systolic Dysfunction: Late Outcomes of CAMERA-MRI Study.


Journal

JACC. Clinical electrophysiology
ISSN: 2405-5018
Titre abrégé: JACC Clin Electrophysiol
Pays: United States
ID NLM: 101656995

Informations de publication

Date de publication:
14 12 2020
Historique:
received: 10 04 2020
revised: 27 07 2020
accepted: 13 08 2020
entrez: 18 12 2020
pubmed: 19 12 2020
medline: 19 8 2021
Statut: ppublish

Résumé

This study sought to determine the long-term outcomes of restoring sinus rhythm with catheter ablation (CA). The CAMERA-MRI (Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Heart Failure-An MRI-Guided Multicenter Randomized Controlled Trial) study demonstrated that restoration of sinus rhythm with CA significantly improved left ventricular ejection fraction (LVEF) compared with medical rate control (MRC) at 6 months in persistent atrial fibrillation and otherwise unexplained systolic heart failure. However, the long-term outcomes have not been reported. Patients enrolled in the CAMERA-MRI study were followed for 4 years with echocardiogram and cardiac magnetic resonance. CA involved pulmonary vein isolation and posterior left atrial wall isolation in 94%. Patients crossed over to CA after 6-month study duration. Arrhythmia burden was determined with implanted cardiac monitors or cardiac devices. Sixty-six patients (age 62 ± 10 years, atrial fibrillation duration of 22 ± 16 months, and LVEF 33 ± 9%) were randomized 1:1 to CA versus MRC. Eighteen of 33 patients crossed over from MRC group to CA group. At 4.0 ± 0.9 years, atrial fibrillation recurred in 27 patients (57%) in the CA group with a mean burden of 10.6 ± 21.2% after 1.4 ± 0.6 procedures. There was an absolute increase in LVEF with CA of 16.4 ± 13.3% compared with 8.6 ± 7.6% in MRC (p = 0.001). In the CA group, the absence of ventricular late gadolinium enhancement was associated with a greater improvement in absolute LVEF (19 ± 13% vs. 10 ± 11% in the late gadolinium enhancement-positive group; p = 0.04) and LVEF normalization in 19 patients (58%) versus 4 patients (18%) in the late gadolinium enhancement-positive group (p = 0.008) at 4.0 ± 0.9 years follow-up. CA is superior to MRC in improving LVEF in the long term in patients with atrial fibrillation and systolic heart failure. The greatest recovery in systolic function was demonstrated in the absence of ventricular fibrosis on cardiac magnetic resonance.

Sections du résumé

OBJECTIVES
This study sought to determine the long-term outcomes of restoring sinus rhythm with catheter ablation (CA).
BACKGROUND
The CAMERA-MRI (Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Heart Failure-An MRI-Guided Multicenter Randomized Controlled Trial) study demonstrated that restoration of sinus rhythm with CA significantly improved left ventricular ejection fraction (LVEF) compared with medical rate control (MRC) at 6 months in persistent atrial fibrillation and otherwise unexplained systolic heart failure. However, the long-term outcomes have not been reported.
METHODS
Patients enrolled in the CAMERA-MRI study were followed for 4 years with echocardiogram and cardiac magnetic resonance. CA involved pulmonary vein isolation and posterior left atrial wall isolation in 94%. Patients crossed over to CA after 6-month study duration. Arrhythmia burden was determined with implanted cardiac monitors or cardiac devices.
RESULTS
Sixty-six patients (age 62 ± 10 years, atrial fibrillation duration of 22 ± 16 months, and LVEF 33 ± 9%) were randomized 1:1 to CA versus MRC. Eighteen of 33 patients crossed over from MRC group to CA group. At 4.0 ± 0.9 years, atrial fibrillation recurred in 27 patients (57%) in the CA group with a mean burden of 10.6 ± 21.2% after 1.4 ± 0.6 procedures. There was an absolute increase in LVEF with CA of 16.4 ± 13.3% compared with 8.6 ± 7.6% in MRC (p = 0.001). In the CA group, the absence of ventricular late gadolinium enhancement was associated with a greater improvement in absolute LVEF (19 ± 13% vs. 10 ± 11% in the late gadolinium enhancement-positive group; p = 0.04) and LVEF normalization in 19 patients (58%) versus 4 patients (18%) in the late gadolinium enhancement-positive group (p = 0.008) at 4.0 ± 0.9 years follow-up.
CONCLUSIONS
CA is superior to MRC in improving LVEF in the long term in patients with atrial fibrillation and systolic heart failure. The greatest recovery in systolic function was demonstrated in the absence of ventricular fibrosis on cardiac magnetic resonance.

Identifiants

pubmed: 33334453
pii: S2405-500X(20)30743-X
doi: 10.1016/j.jacep.2020.08.019
pii:
doi:

Substances chimiques

Contrast Media 0
Gadolinium AU0V1LM3JT

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1721-1731

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Author Disclosures Dr. Sugumar has received support from a co-funded National Health and Medical Research Committee/National Health Foundation post-graduate scholarships and Royal Australian College of Physicians J.J. Billings and Centre of Research Excellence in Cardiovascular Outcomes Improvement scholarships. Prof. Jonathan M. Kalman has received a National Health and Medical Research Committee practitioner fellowship; and research and fellowship support from Medtronic and Biosense Webster, all outside the submitted work. Prof. Kistler has received funding from Abbott Medical for consultancy and speaking engagements, outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Hariharan Sugumar (H)

Department of Cardiology, The Baker Heart Research Institute, Melbourne, Australia; Department of Cardiology, The Alfred Hospital, Melbourne, Australia; Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia; Department of Cardiology, University of Melbourne, Melbourne, Australia.

Sandeep Prabhu (S)

Department of Cardiology, The Baker Heart Research Institute, Melbourne, Australia; Department of Cardiology, The Alfred Hospital, Melbourne, Australia; Department of Cardiology, University of Melbourne, Melbourne, Australia.

Ben Costello (B)

Department of Cardiology, The Baker Heart Research Institute, Melbourne, Australia; Department of Cardiology, The Alfred Hospital, Melbourne, Australia.

David Chieng (D)

Department of Cardiology, The Baker Heart Research Institute, Melbourne, Australia; Department of Cardiology, The Alfred Hospital, Melbourne, Australia; Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia; Department of Cardiology, University of Melbourne, Melbourne, Australia.

Sonia Azzopardi (S)

Department of Cardiology, The Baker Heart Research Institute, Melbourne, Australia; Department of Cardiology, The Alfred Hospital, Melbourne, Australia.

Aleksandr Voskoboinik (A)

Department of Cardiology, The Baker Heart Research Institute, Melbourne, Australia; Department of Cardiology, The Alfred Hospital, Melbourne, Australia; Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia; Department of Cardiology, University of Melbourne, Melbourne, Australia.

Ramanathan Parameswaran (R)

Department of Cardiology, The Alfred Hospital, Melbourne, Australia; Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia; Department of Cardiology, University of Melbourne, Melbourne, Australia.

Geoffrey R Wong (GR)

Department of Cardiology, The Alfred Hospital, Melbourne, Australia; Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia; Department of Cardiology, University of Melbourne, Melbourne, Australia.

Robert Anderson (R)

Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia; Department of Cardiology, University of Melbourne, Melbourne, Australia.

Ahmed M Al-Kaisey (AM)

Department of Cardiology, The Alfred Hospital, Melbourne, Australia; Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia; Department of Cardiology, University of Melbourne, Melbourne, Australia.

Liang-Han Ling (LH)

Department of Cardiology, The Alfred Hospital, Melbourne, Australia; Department of Cardiology, University of Melbourne, Melbourne, Australia.

Emily Kotschet (E)

Department of Cardiology, Monash Health, Melbourne, Australia.

Andrew J Taylor (AJ)

Department of Cardiology, The Baker Heart Research Institute, Melbourne, Australia; Department of Cardiology, The Alfred Hospital, Melbourne, Australia.

Jonathan M Kalman (JM)

Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia; Department of Cardiology, University of Melbourne, Melbourne, Australia.

Peter M Kistler (PM)

Department of Cardiology, The Baker Heart Research Institute, Melbourne, Australia; Department of Cardiology, The Alfred Hospital, Melbourne, Australia; Department of Cardiology, University of Melbourne, Melbourne, Australia. Electronic address: peter.kistler@baker.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH